KEYTRUDA plus LENVIMA is the first and only combination for the first-line treatment of advanced renal cell carcinoma (RCC) with data in both clear cell and non-clear cell RCC in the US label NUTLEY, N.J., June 27, 2024 /PRNewswire/ — Eisai today announced a label update for LENVIMA, the…

NEW YORK, June 27, 2024 /PRNewswire/ — The global exfoliators and scrubs market size is estimated to grow by USD 658.7 million from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of 4.36% during the forecast period. Rise in demand for skin-lightening…

TEMPE, Ariz., June 27, 2024 /PRNewswire/ — The board of directors of GoDaddy Inc. (NYSE: GDDY) unanimously elected Graham Smith as a new independent director effective June 26, 2024. He will serve as a Class I director until the company’s 2025 annual meeting of stockholders, at which…

Development Candidate targets Glypican-3 for the treatment of solid tumors, including hepatocellular carcinoma Nomination triggers a $2 million milestone payment to Carisma PHILADELPHIA, June 27, 2024 /PRNewswire/ — Carisma Therapeutics Inc. (Nasdaq: CARM) (“Carisma” or the “Company”), a…

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.